If everyone seems to be sick around you, you are not imagining it. The flu season is arriving in the United States unusually early and much more difficult than general.
“I am afraid of what will happen in this flu season because I do not think we have seen a coalition of multiple viruses that manifest in this way,” said Dr. Elizabeth Clayborne, professor of urgent Medicine and Associated Medicine of the University of Maryland. Covid precautions have led to lower rates of flu-like diseases compared to normal pre-plants. But now that much of the United States has abandoned preventive measures, such as masking, more people get sick with seasonal diseases.
“All models of mixing and transmission of several viruses really decreased from that arrest,” said Dr. Andrea Berry, an associated professor of pediatrics and medicine at the University of Maryland’s faculty. “As the world has opened, the usual schemes are not exactly the same.”
One of those diseases similar to flu is respiratory synchronization, or RSV, which is more serious in young children, older people, and immunocompromised.
More cases of RSV have been reported every week of October than any other week in the last two years, and doctors throughout the country have been increasing the alarm by the overwhelming number of hospitals this season.
Like the RSV, the cases of influence began to increase earlier this year, with the centers for the control and prevention of diseases that reported at least 1,600,000 cases, 13,000 hospitalizations, and 730 deaths as of October 29, which is high for this at the beginning of a typical flu season.
Clayborne’s 2 -year -old raw and 4 years old had RSV at the end of September and their eldest daughter had to be taken to the emergency room to receive treatment.
“I know that [the flu and the RSV are] common and it seems that many children understand them,” Clayborne said. “But let’s see that children always die, and it is generally due to respiratory complications.”
There is currently no federal vaccine for the treatment of RSV, but Pfizer reported in early November that his candidate for the RSV vaccine in his experimentation of phase 3, which was administered to mothers during pregnancy, was almost 70% Effective to protect against serious symptoms in less than 6 months of months.
